证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|----------------------------------|----------------------------------------|--------------------------------------------------------| | | | | 编号： 2021-006 | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | 个人投资者：郑圣 | | | | 时间 | 2021 年 9 月 24 日上午 | 10 ： 00 | | | 地点 | 公司三楼小会议室 | | | | 上市公司接待人 | 证券事务代表王燕红 | | | | 员姓名 | 证券事 ...

1 证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |----------------------------|--------------------------------|-----------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投 资 者关 系活动 | | □媒体采访 □业绩说明会 | | 类别 | | □新闻发布会 □路演活动 | | | □现场参观 | | | | 其他（电话） | | | | 中金 刘锡源，深国投 | - 尚雅 1 期 成佩剑 | | | | TEMASEK FULLERTON ALPHA PTE LTD SunTony | | | | 长城财富保险资产管理股份有限公司 胡纪元 | | | 中国通用技术 ( 集团 ) | 控股有限责任公司 程偲 | | | | 瀚伦投资大中华直通车私募投资基金 任靖 | | | | 上海勤辰私募基金管理合伙企业（有限合伙） 崔 ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------------------------|-------| | | | 特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | | | | | 其他（电话） | | | | | | 东吴证券研究所朱国广、徐梓煜、乔波耀、李倩 | | | | Pinpoint 卢聪， TKAMC | 刘勍，东方证券资管江琦 | | | | | 国海资管吴正明，国泰基金黄卓，泓澄投资殷萌 | | | | | 竑观投资朱戈宇，华夏财富程海泳，嘉实基金程佳、孙晓晖 | | | | | 建信郑丁源，江海自营罗萍，金元证券黄斌， | | | | | 景泰 ...

Financial Performance - The company's revenue for Q3 2022 was ¥359,329,021.98, representing a 1.75% increase year-over-year, while the year-to-date revenue reached ¥1,063,113,569.06, up 7.72% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥29,171,223.85, a significant increase of 203.43% year-over-year, with a year-to-date net profit of ¥108,275,724.51, reflecting a 44.00% increase[4] - The basic earnings per share for Q3 2022 was ¥0.31, marking a 210.00% increase compared to the same period last year, while the diluted earnings per share also stood at ¥0.31[4] - Total operating revenue for the third quarter reached ¥1,063,113,569.06, an increase of 7.8% compared to ¥986,885,462.15 in the same period last year[25] - The net profit for the third quarter of 2022 was CNY 113,440,888, an increase of 23.5% compared to CNY 91,813,306 in the same period last year[26] - The operating profit for the quarter was CNY 125,537,781, up from CNY 118,904,972, reflecting a growth of 5.4%[26] - The total revenue from sales of goods and services reached CNY 1,304,612,965, compared to CNY 1,142,063,944 in the previous year, marking an increase of 14.2%[27] - Basic and diluted earnings per share for the quarter were both CNY 1.15, up from CNY 0.78 in the previous year, representing a growth of 47.4%[27] - The total comprehensive income attributable to the parent company was CNY 108,275,725, compared to CNY 75,194,012 in the same period last year, reflecting a growth of 43.9%[26] Assets and Liabilities - The company's total assets as of September 30, 2022, were ¥2,427,816,704.62, a 16.52% increase from the end of the previous year[4] - Current assets decreased to ¥1,284,732,436.21 from ¥1,375,955,724.32, indicating a reduction in liquidity[22] - Total liabilities rose to ¥851,494,145.14 from ¥608,642,637.36, indicating increased financial obligations[23] - The company's equity attributable to shareholders increased to ¥1,432,424,818.35 from ¥1,338,853,095.62, reflecting retained earnings growth[23] Cash Flow - The net cash flow from operating activities for the first nine months of 2022 was ¥213,947,191.32, a 37.19% increase year-over-year, driven by higher cash receipts from sales[9] - The cash flow from operating activities generated a net amount of CNY 213,947,191, which is an increase of 37.2% from CNY 155,946,945 in the same period last year[27] - The company's cash flow from financing activities for the first nine months of 2022 was ¥200,579,871.01, a notable change from a cash outflow of ¥130,561,802.81 in the previous year, primarily due to new bank loans[9] - The financing activities resulted in a net cash inflow of CNY 200,579,871, reversing the outflow of CNY 130,561,803 from the same period last year[29] - The cash and cash equivalents at the end of the period were CNY 603,970,655, down from CNY 733,663,744 at the end of the previous year[29] Investments - The company reported a 503.00% increase in long-term equity investments, totaling ¥546,571,677.93, due to increased investments in joint ventures[8] - The company’s net profit from investment activities for the first nine months of 2022 was ¥7,502,078.82, a significant improvement compared to a loss of ¥14,467,528.91 in the same period last year[9] - The company reported an investment income of ¥7,502,078.82, a recovery from a loss of ¥14,467,528.91 in the previous year[25] - The company has completed the acquisition of 15.74% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 157.48 million[14] - The company plans to acquire an additional 38.22% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 191.30 million, pending shareholder approval[16] - The company has engaged in a strategic investment in Guangdong Yiduoli Biotechnology Co., Ltd. for RMB 200 million[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,259[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 34,000,000 shares, with 13,825,000 shares pledged[11] - The top ten shareholders collectively hold 60.30% of the company's shares, indicating a concentrated ownership structure[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to ¥66,481,632.41, an increase of 82.54% compared to the same period in 2021, indicating a significant investment in innovation[9] - Research and development expenses increased significantly to ¥66,481,632.41, compared to ¥36,419,433.88 in the previous year, reflecting a focus on innovation[25] Inventory and Accounts Payable - The company experienced a 141.59% increase in accounts payable, reaching ¥232,839,776.00, attributed to an increase in issued payables during the reporting period[8] - Inventory levels increased to ¥371,298,600.06, up from ¥299,602,396.21, suggesting a buildup of stock[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥703,784,547.08, representing an increase of 11.05% compared to ¥633,728,939.83 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2022 was ¥79,104,500.66, a 20.62% increase from ¥65,580,207.38 in the previous year[26]. - The net cash flow from operating activities increased by 61.37% to ¥212,313,335.25, up from ¥131,571,852.44 in the same period last year[26]. - The total assets at the end of the reporting period were ¥2,356,716,745.93, reflecting a growth of 13.11% from ¥2,083,578,310.62 at the end of the previous year[26]. - The company’s basic earnings per share increased by 23.53% to ¥0.84, compared to ¥0.68 in the same period last year[26]. - The company's operating profit for the first half of 2022 was ¥93.83 million, up 6.66% from ¥87.88 million in the first half of 2021[190]. - The company achieved an investment income of ¥6.56 million, a recovery from a loss of ¥5.63 million in the first half of 2021[190]. - The tax expense for the first half of 2022 was ¥7.75 million, down 33.06% from ¥11.59 million in the previous year[190]. Research and Development - The company is focused on enhancing its research and development capabilities to drive innovation in its product offerings[5]. - Research and development expenses rose significantly by 73.14% to ¥39,657,679.88, reflecting the company's increased investment in R&D[56]. - The company has made significant progress in its R&D projects, with several key generic drugs either approved or in various stages of registration[48]. - Anglikang is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and safety[131]. - The company plans to launch three new products in the next quarter, targeting a market share increase of 10% in the respective segments[131]. Market Strategy and Expansion - The company is actively pursuing market expansion strategies and potential mergers and acquisitions to strengthen its market position[5]. - The pharmaceutical industry is expected to grow due to increasing demand driven by an aging population and high-end medical needs, despite regulatory pressures[34]. - The company is exploring market expansion opportunities in Southeast Asia, with a projected revenue increase of 20% from this region by the end of 2023[131]. - The company has initiated discussions for potential mergers and acquisitions to strengthen its market position, focusing on companies with complementary product lines[131]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 20% increase in market share[133]. Risk Management - The company emphasizes the importance of risk factors including regulatory changes, rising production costs, and the impact of the ongoing pandemic on operations[5]. - The company has outlined potential risks related to talent retention and the loss of core technical personnel, which could impact future growth[5]. - The company faces ongoing risks of rising production costs and drug price reductions due to national policies, which may compress profit margins while providing opportunities for sales expansion[89]. - The company is monitoring the ongoing pandemic situation, which could adversely affect operations if outbreaks occur[95]. - The company is at risk of talent shortages and core technical personnel turnover, which could impact operational efficiency; it plans to enhance talent recruitment and internal training[93]. Environmental and Social Responsibility - The company has highlighted the importance of environmental policies and safety production measures in its operational strategy[5]. - The company has established wastewater treatment facilities with a capacity of 1000t/d at its headquarters and Jiangsu Yuexin, and 72t/d at Haixi Pharmaceutical, all operating normally[107]. - The company’s wastewater discharge meets the standards set by relevant environmental regulations, with ammonia nitrogen and total phosphorus controlled according to specific limits[108]. - The company actively participates in social welfare activities, donating 1 million to the Shenzhou Charity Association after the reporting period[121]. - The company emphasizes social responsibility, focusing on economic benefits while protecting stakeholders' rights, particularly employees and customers[115]. Corporate Governance - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team[4]. - The company has a comprehensive governance structure in place to oversee its operations and ensure compliance with regulatory requirements[4]. - The company has established a comprehensive corporate governance structure to protect shareholder and creditor rights, ensuring transparency and fairness in information disclosure[116]. - The company prioritizes employee welfare, providing a supportive work environment and adhering to labor laws to protect employee rights[118]. Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months following the listing of its stock[124]. - The company will notify the market in writing about any intention to reduce its holdings of shares, with a notice period of 3 trading days[124]. - The company has committed to strict compliance with regulations regarding shareholder reductions and will notify the company of any intended share reductions[126]. - The company has not reported any violations of these commitments as of the current date[126]. Financial Management - The company reported a government subsidy income of ¥3,717,386.51 during the reporting period, contributing positively to its financial performance[30]. - The company reported a significant decrease of 82.99% in notes receivable, down to ¥5,380,148.21, due to the maturity of accepted bills[63]. - The company has established a joint venture named Jianrui Pharmaceutical with Hunan Kairui Biological, which was registered in June 2022[144]. - The company has cumulatively obtained 23.48% of Keri Pharmaceutical through agreements and block trades as of the report signing date[159].

Financial Performance - The company's revenue for Q1 2022 was CNY 338,209,274.21, representing a 6.06% increase compared to CNY 318,879,719.41 in the same period last year[4] - Net profit attributable to shareholders was CNY 39,086,498.56, up 19.23% from CNY 32,782,577.42 year-over-year[4] - Basic earnings per share rose to CNY 0.41, a 20.59% increase from CNY 0.34 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 338,209,274.21, an increase of 6.6% compared to CNY 318,879,719.41 in Q1 2021[27] - Net profit for Q1 2022 reached CNY 42,077,608.52, representing a 15.5% increase from CNY 36,576,577.16 in Q1 2021[28] - Earnings per share for Q1 2022 were CNY 0.41, compared to CNY 0.34 in Q1 2021, indicating a growth of 20.6%[29] Cash Flow - The net cash flow from operating activities increased by 70.74%, reaching CNY 89,918,248.97 compared to CNY 52,662,779.65 in Q1 2021[12] - Total cash inflow from operating activities amounted to ¥456,326,128.89, while cash outflow was ¥366,407,879.92, resulting in a net inflow of ¥89,918,248.97[32] - The net cash flow from investing activities was -¥201,224,708.39, a significant decline from -¥42,650,301.10 in the previous year[33] - Cash inflow from financing activities totaled ¥122,000,000.00, while cash outflow was ¥331,880.05, leading to a net cash inflow of ¥121,668,119.95[33] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 2,245,359,613.67, reflecting a 7.76% increase from CNY 2,083,578,310.62 at the end of the previous year[4] - Total liabilities increased to CNY 726,146,304.21 in Q1 2022 from CNY 608,642,637.36 in Q1 2021, representing a rise of 19.3%[25] - The company's total non-current assets reached CNY 896,002,288.39 in Q1 2022, up from CNY 707,622,586.30 in Q1 2021, indicating a growth of 26.7%[25] Investments - The company reported a significant increase in long-term equity investments by 216.76%, totaling CNY 287,112,626.94 due to increased investments in joint ventures[10] - The company experienced a 371.80% increase in cash flow from investing activities, resulting in a net outflow of CNY 201,224,708.39, primarily due to increased investments in joint ventures[12] - The company plans to acquire a 12.55% stake in Hunan New He New Biopharmaceutical Co., Ltd. for RMB 20,000,000[18] - The company has completed the acquisition of 23.48% of Hunan Keri Biopharmaceutical Co., Ltd. for RMB 15,747,690[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,264[13] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., held a 35.44% stake in the company[13] - The company repurchased a total of 2,060,000 shares, representing 2.15% of the total share capital, with a total transaction amount of RMB 63,330,916[16] Operational Expenses - Total operating costs for Q1 2022 were CNY 292,776,746.73, up from CNY 281,195,280.82 in the same period last year, reflecting a year-on-year increase of 4.6%[27] - The company reported a decrease in sales expenses to CNY 133,286,139.03 in Q1 2022 from CNY 144,055,029.38 in Q1 2021, a reduction of 7.5%[28] - Research and development expenses for Q1 2022 amounted to CNY 14,730,302.82, up from CNY 11,344,978.86 in Q1 2021, marking a 30.5% increase[28] Other Financial Activities - The company has applied for a bank loan of up to RMB 30,000,000, with RMB 19,000,000 already drawn down[17] - The company is in the process of planning a major asset restructuring through a share issuance[21] - The first phase of the employee stock ownership plan is under consideration and requires shareholder approval[20] - The company did not conduct an audit for the Q1 report, as indicated in the audit report[34]

Financial Performance - The company's operating revenue for 2021 was ¥1,380,377,636.93, representing a 7.04% increase compared to ¥1,289,647,101.26 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥119,844,202.86, a decrease of 26.80% from ¥163,719,116.52 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥107,857,508.30, down 19.51% from ¥134,000,807.56 in 2020[18]. - The company's total assets at the end of 2021 were ¥2,083,578,310.62, an increase of 7.36% from ¥1,940,754,044.72 at the end of 2020[18]. - The basic earnings per share for 2021 was ¥1.27, a decline of 29.83% compared to ¥1.81 in 2020[18]. - The weighted average return on net assets decreased to 9.13% in 2021 from 16.11% in 2020, a drop of 6.98 percentage points[18]. - The net cash flow from operating activities for 2021 was ¥197,652,364.35, a slight decrease of 0.48% from ¥198,612,986.30 in 2020[18]. - The company reported a total of ¥11,986,694.56 in non-recurring gains for 2021, down from ¥29,718,308.96 in 2020[24]. Market Expansion and Product Development - The company is actively involved in new product development and has faced challenges with the consistency evaluation of major products[4]. - The company has expanded its market presence by acquiring a controlling stake in Haixi United Pharmaceutical Co., Ltd. in August 2021[12]. - The company is focusing on expanding its product line with new drugs, although future production and sales remain uncertain for many of these products[64][65]. - The company completed the registration of three new products, including compound α-keto acid tablets and sevoflurane raw materials[41]. - The company is actively expanding into new markets, including pet pharmaceuticals and medical aesthetics, through strategic partnerships and joint ventures[43]. Research and Development - The company is focused on enhancing its R&D capabilities to innovate and develop new drugs, particularly in the field of generic drugs[4]. - R&D investment has been increased to enhance project progress and attract high-end talent, focusing on differentiated competitive products in the pharmaceutical sector[41]. - The company has several new drug projects in progress, including the approval of Ticagrelor tablets and the completion of bioequivalence studies for various products[64][65]. - The number of R&D personnel increased by 22.89% to 102 in 2021 from 83 in 2020[66]. - The company plans to increase its R&D investment to enhance its core competitiveness and accelerate the development of new products, including the "HC008" project and the expansion of alpha-keto acid raw material production[108]. Risk Management - The company acknowledges various risks including rising production costs, regulatory changes, and the impact of the ongoing pandemic on operations[4]. - The company has highlighted the need for risk awareness among investors regarding potential unlisted risks[4]. - The company acknowledges the risks associated with new product development, including potential delays and failures, and plans to implement rigorous project management to mitigate these risks[117]. - The company is prepared to address the ongoing impacts of the pandemic on its operations, ensuring that production and business activities are organized effectively[119]. - The company is actively monitoring industry regulatory changes and will adapt its internal management to comply with new standards, aiming to maintain operational stability[109]. Governance and Compliance - The company emphasizes the protection of minority shareholders' rights and has conducted shareholder meetings in compliance with legal requirements, ensuring transparency and fairness[128]. - The board of directors operates with a clear division of responsibilities and has established four specialized committees to provide professional opinions for decision-making[129]. - The company adheres to strict information disclosure practices, complying with relevant laws and regulations to maintain transparency[130]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[191]. - The company has identified no violations of national regulations or the China Securities Regulatory Commission's requirements during its governance self-inspection[177]. Environmental and Social Responsibility - The company has established wastewater treatment facilities with a design capacity of 1,000 tons per day at its headquarters and Jiangsu Yuexin, and 72 tons per day at Haixi Pharmaceutical, all operating normally[182]. - The company has implemented a robust environmental management system that meets pollution control requirements and ensures stable compliance with discharge standards[182]. - The company has achieved ISO14001 certification for its environmental management system, reflecting its commitment to environmental protection[194]. - The company has actively participated in social welfare activities, including donations of epidemic prevention materials and support for underprivileged families[195]. - The company has implemented a comprehensive review of its governance structure, financial operations, and compliance with regulatory requirements, leading to identified areas for improvement[177]. Shareholder and Financial Policies - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 93,886,819 shares[4]. - The company maintained a transparent and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[169]. - The total cash dividend, including other methods, reached RMB 91,505,097.05 for the reporting period[169]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing, with a lock-up period extending for an additional 6 months if certain conditions are met[198]. - The company must notify the stock exchange of any intended share reductions 3 trading days in advance[200].

Financial Performance - The company's revenue for Q3 2021 was ¥353,156,522.32, representing a 13.80% increase year-over-year, while the year-to-date revenue reached ¥986,885,462.15, up 7.47% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥9,613,804.84, a significant decrease of 75.45% year-over-year, with a year-to-date net profit of ¥75,194,012.22, down 39.47% compared to the previous year[5] - The basic earnings per share for Q3 2021 was ¥0.1, down 77.27% year-over-year, while the diluted earnings per share also stood at ¥0.1, reflecting the same percentage decrease[5] - Total operating revenue for the third quarter reached ¥986,885,462.15, an increase of 7.4% compared to ¥918,248,206.67 in the same period last year[25] - Net profit for the period was ¥91,813,306.34, a decrease of 32.6% from ¥136,218,844.80 in the previous year[26] - Earnings per share (EPS) for the quarter was ¥0.78, down from ¥1.38 in the same quarter last year[27] Assets and Liabilities - The total assets as of September 30, 2021, were ¥1,896,558,214.32, a decrease of 2.28% from the end of the previous year[5] - Total liabilities decreased to ¥477,703,549.91 from ¥562,784,336.85, indicating a reduction of 15.1%[26] - Total assets stood at ¥1,896,558,214.32, down from ¥1,940,754,044.72, a decline of 2.3%[23] - The company's equity attributable to shareholders was ¥1,292,984,735.47, a slight decrease from ¥1,318,879,304.06[23] Cash Flow - The company reported a cash flow from operating activities for the year-to-date period of ¥155,946,945.13, down 13.65% compared to the previous year[5] - Cash generated from operating activities was ¥1,142,063,943.84, an increase of 10.6% from ¥1,032,880,810.74 in the prior year[28] - Net cash flow from operating activities was CNY 155,946,945.13, down from CNY 180,596,804.44 year-over-year[29] - Cash outflow from investing activities amounted to CNY 145,416,190.32, compared to CNY 89,807,824.18 in the same period last year[30] - Net cash flow from investing activities was negative at CNY -138,536,567.17, a decline from CNY 64,174,832.93 in the previous year[30] - Cash flow from financing activities showed a net outflow of CNY -130,561,802.81, compared to CNY -80,410,058.73 in the prior year[30] - The ending balance of cash and cash equivalents was CNY 733,663,744.32, down from CNY 614,874,919.60 year-over-year[30] Operating Costs and Expenses - The company experienced a 108.52% increase in operating costs, totaling ¥352,084,659.27, attributed to higher raw material costs due to increased sales[11] - Total operating costs amounted to ¥863,524,820.55, up 10.5% from ¥781,069,251.21 year-on-year[25] - Research and development expenses increased to ¥36,419,433.88, compared to ¥28,790,171.53 in the previous year, reflecting a growth of 26.5%[25] Investments and Shareholder Information - The company has increased its investment in construction projects, with construction in progress rising by 38.00% to ¥156,036,520.46, indicating ongoing expansion efforts[10] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 34,000,000 shares[15] - The company has repurchased a total of 2,060,000 shares, accounting for 2.15% of the total share capital, with a total transaction amount of 63,330,916 RMB[17] - The company invested 40 million RMB in Jiaxing Yuanlai Yuanqi Venture Capital Partnership[17] - The company established a joint venture with Zhejiang Haichang Biopharmaceutical Technology Co., Ltd.[18] - The company increased its investment in Fujian Haixi United Pharmaceutical Co., Ltd. by 46.875 million RMB[19] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 218.49% to ¥14,415,203.81, primarily due to increased advance payments for raw materials[10] - The company reported a significant increase in interest income to ¥20,495,291.91 from ¥13,738,659.56, marking a growth of 49.8%[26] - The company reported a 341.77% increase in asset impairment losses, amounting to ¥1,531,771.52, primarily due to inventory write-downs[12] - The company did not adjust the beginning balance sheet items due to the new leasing standards, as there were no leasing contracts prior to January 1, 2021[31] - The third-quarter report was not audited[32]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was RMB 100 million, up 20% compared to the same period last year[15]. - The company's operating revenue for the first half of 2021 was ¥633,728,939.83, an increase of 4.24% compared to ¥607,928,301.13 in the same period last year[20]. - Net profit attributable to shareholders decreased by 22.91% to ¥65,580,207.38 from ¥85,071,573.20 year-on-year[20]. - The company achieved total revenue of CNY 63,372.89 million for the first half of 2021, representing a year-on-year growth of 4.24%[33]. - The net profit attributable to shareholders was CNY 6,558.02 million, a decrease of 22.91% compared to the same period last year, primarily due to a significant decline in government subsidies received[33]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2021, representing a 25% year-over-year growth[111]. - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 25%[111]. Research and Development - The company plans to invest RMB 50 million in R&D for new drug development in the next fiscal year[15]. - The company is focusing on the development of generic drugs, with 5 new products expected to be launched in the next 12 months[15]. - The company has made progress in the development of key generic drug projects, including the completion of registration for Ticagrelor tablets and the submission of applications for other products[35]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficacy[111]. - The company continues to focus on R&D and innovation, aiming to develop high-value generic drugs and maintain a robust product pipeline[38]. Market Expansion - User data indicates a 30% increase in the number of active customers, reaching 1 million by the end of June 2021[15]. - The company has expanded its market presence by entering two new provinces, aiming for a 10% market share in these regions by the end of 2022[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[107]. - Market expansion plans include entering three new provinces in China, targeting a 15% market share by 2023[111]. Strategic Initiatives - The company is exploring strategic partnerships for potential mergers and acquisitions to enhance its product portfolio[15]. - A strategic acquisition of a smaller biotech firm was announced, expected to enhance the company's R&D capabilities and add 150 million CNY in annual revenue[107]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for potential deals[111]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the next three years[107]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[83]. - The company has committed to ensuring effective implementation of measures to compensate for immediate returns dilution following its public offering[112]. Environmental and Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[74]. - The company has strengthened its quality management system and implemented a comprehensive environmental, health, and safety (EHS) management system to ensure compliance and safety in production[37]. - The company ensures that all emissions from its production processes comply with relevant environmental standards, including strict limits on VOCs and other pollutants[76]. - The company has implemented a comprehensive monitoring system for wastewater, ensuring that all treated wastewater meets discharge standards before entering municipal systems[75]. Risks and Challenges - The management highlighted potential risks including regulatory changes and rising production costs, which could impact future performance[5]. - The company faces risks from rising production costs due to stricter national safety and environmental policies, which could impact profitability[60]. - The company is at risk of not passing the consistency evaluation for its generic drugs, which could affect market access and future operations[64]. Shareholder and Governance - The company has appointed new directors and a financial director as part of its board restructuring on January 5, 2021[69]. - The company has established a commitment to avoid engaging in any business that competes with its main operations[99]. - The company has a strategy to maintain transparency and compliance with the China Securities Regulatory Commission[94]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing[92].

Revenue and Profit - The company's revenue for Q1 2021 was CNY 318,879,719.41, representing a 4.28% increase compared to CNY 305,801,306.93 in the same period last year[7] - Net profit attributable to shareholders decreased by 21.56% to CNY 32,782,577.42 from CNY 41,793,775.21 year-on-year[7] - The net profit after deducting non-recurring gains and losses increased by 11.03% to CNY 31,269,592.62 compared to CNY 28,162,927.11 in the previous year[7] - Net profit for Q1 2021 was CNY 36,576,577.16, a decrease from CNY 44,118,468.41 in the same period last year, representing a decline of approximately 17%[43] - Total comprehensive income for the first quarter was CNY 27,436,753.47, compared to CNY 41,876,969.19 in the previous period, indicating a decrease of approximately 34.5%[48] Cash Flow - The net cash flow from operating activities was CNY 52,662,779.65, down 48.91% from CNY 103,085,670.64 in the same period last year[7] - Cash inflow from operating activities totaled CNY 396,086,372.02, a decrease from CNY 418,141,711.73 in the previous year[51] - Cash outflow from operating activities increased to CNY 343,423,592.37, compared to CNY 315,056,041.09 in the previous period, reflecting a rise of approximately 9.0%[51] - Investment activities resulted in a net cash outflow of CNY 42,650,301.10, a significant decrease from a net inflow of CNY 125,806,840.90 in the previous year[51] - The company reported a cash flow from financing activities net outflow of CNY 27,023,620.47, compared to a net inflow of CNY 9,889,031.66 in the previous year[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,881,859,623.93, a decrease of 3.03% from CNY 1,940,754,044.72 at the end of the previous year[7] - Current assets totaled CNY 1,316,295,205.04, down from CNY 1,393,396,544.53, indicating a decrease of about 5.55%[33] - Total liabilities decreased to CNY 476,082,970.53 from CNY 562,784,336.85, a decline of around 15.38%[35] - The total liabilities increased to CNY 380,923,351.54 from CNY 378,385,218.39 year-over-year[42] - The company's equity increased to CNY 1,405,776,653.40 from CNY 1,377,969,707.87, an increase of about 2.84%[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,322[10] - The company repurchased 514,900 shares, accounting for 0.54% of total equity, with a total transaction amount of ¥16,976,813[18] - The company plans to use between ¥50 million and ¥100 million for share repurchase, with a maximum price of ¥55.00 per share[17] Operating Costs and Expenses - Operating costs rose by 124.87% to ¥109,763,926.03 primarily due to increased raw material revenue[16] - Research and development expenses for Q1 2021 were CNY 11,344,978.86, slightly up from CNY 10,435,352.69 year-over-year[42] - The company reported a decrease in sales expenses to CNY 144,055,029.38 from CNY 195,476,379.49 in the previous year[42] Non-Recurring Gains and Losses - The company reported non-recurring gains of CNY 1,512,984.80, primarily from government subsidies and other income[8] - The company reported a significant decrease in other income by 88.14% to ¥1,787,010.20 due to reduced government grants[16] - Investment income decreased by 840.62% to -¥3,273,488.22 due to increased losses from joint ventures[16] Other Financial Metrics - Basic and diluted earnings per share decreased by 26.09% to CNY 0.34 from CNY 0.46 year-on-year[7] - The weighted average return on equity was 2.45%, down from 4.24% in the previous year, a decrease of 1.79%[7] - The company has no violations regarding external guarantees during the reporting period[26] - The company did not adjust the beginning balance of the balance sheet for the new leasing standards, indicating no significant impact on financial results[57]